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Abstract
Background: Artemisinin-based combination therapy is currently recommended worldwide for the treatment of
uncomplicated malaria. Fixed-dose combinations are preferred as they favour compliance. This paper reports on
the initial phases of the pharmaceutical development of an artesunate-amodiaquine (ASAQ) bilayer co-formulation
tablet, undertaken following pre-formulation studies by a network of scientists and industrials from institutions of
both industrialized and low income countries.
Methods: Pharmaceutical development was performed by a research laboratory at the University Bordeaux
Segalen, School of Pharmacy, for feasibility and early stability studies of various drug formulations, further
transferred to a company specialized in pharmaceutical development, and then provided to another company for
clinical batch manufacturing. The work was conducted by a regional public-private not-for-profit network (TropiVal)
within a larger Public Private partnership (the FACT project), set up by WHO/TDR, Médecins Sans Frontières and the
Drugs for Neglected Disease initiative (DNDi).
Results: The main pharmaceutical goal was to combine in a solid oral form two incompatible active principles
while preventing artesunate degradation under tropical conditions. Several options were attempted and failed to
provide satisfactory stability results: incorporating artesunate in the external phase of the tablets, adding a pH
regulator, alcoholic wet granulation, dry granulation, addition of an hydrophobic agent, tablet manufacturing in
controlled conditions. However, long-term stability could be achieved, in experimental batches under GMP
conditions, by physical separation of artesunate and amodiaquine in a bilayer co-formulation tablet in alu-alu
blisters. Conduction of the workplan was monitored by DNDi.
Conclusions: Collaborations between research and industrial groups greatly accelerated the process of
development of the bi-layered ASAQ tablet. Lack of public funding was the main obstacle hampering the
development process, and no intellectual property right was claimed. This approach resulted in a rapid technology
transfer to the drug company Sanofi-Aventis, finalizing the process of development, registration and WHO pre-
qualification of the fixed-dose co-formulation together with DNDi. The bi-layered tablet is made available under
the names of Coarsucam
® and Artesunate amodiaquine Winthrop
®, Sanofi-Aventis. The issue related to the
difficulty of public institutions to valorise their participation in such initiative by lack of priority and funding of
applied research is discussed.
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The World Health Organization (WHO) currently
recommends artemisinin-based combination therapy
(ACT) for the treatment of uncomplicated Plasmodium
falciparum malaria [1]. Virtually all malaria endemic
countries have adopted by now an ACT as first-line
treatment. Initially only individually formulated com-
pounds were available; subsequently, products were co-
blistered. In both cases patient’s adherence may be com-
promised. This called for the development of fixed-dose
co-formulations (FDC). However combining two anti-
malarial drugs into a single tablet may be challenging,
and requires compliance to stringent regulatory
requirements.
The first FDC ACT ever registered was artemether
plus lumefantrine (Coartem
® and Riamet
®,N o v a r t i s )
launched in 2001. Other widely-used combinations at
that time were artesunate plus amodiaquine and artesu-
nate plus mefloquine.
The Special Programme for Research and Training in
Tropical Diseases of the WHO (TDR) initiated explora-
tory pharmaceutical work on anti-malarial drug associa-
tions based on AS and AQ [2], under its Resistance And
Policy (RAP) taskforce at the University of Bordeaux 2,
France local consortium TropiVal [3] and the University
Sains Malaysia.
Later, this project became part of the fixed artemisi-
nin-based combination treatment (FACT) project, led by
the DNDi and TDR. The FACT project received initial
funding of the European Commission (INCO-DEV) and
MSF, and then became largely DNDi self-funded. The
FACT aimed at developing two fixed-dose combinations:
artesunate plus amodiaquine (ASAQ) and artesunate
plus mefloquine (ASMQ) [4,5]. Initially, the network
involved only partners from the public and non-for-
profit sector (Figure 1).
The target product profile (see Table 1) set for the
ASAQ was for a fixed-dose fast-release oral formulation
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Page 2 of 12combining AS and AQ for paediatric use in tropical
conditions (climatic zone IV, hot and humid; [6]). Beside
stability, the target product profile requires also adapted
dose ranges for the tablets for both active components,
minimal excipient quantities to keep tablets small as
well as rapid disintegration for ease of use particularly
in children. This paper relates the development of an
oral ASAQ formulation. The local consortium in Bor-
deaux TropiVal [3] comprised the Laboratory of Bio-
pharmacy, Bordeaux 2 University, School of Pharmacy,
France, and later ELLIPSE Pharmaceuticals, a university
start-up specialized in drug development and process
validation. Analytical methods were developed by the
University Sains Malaysia (USM) and then transferred
to Bordeaux2 University. The University of Oxford, UK
and the National Centre for Research and Training in
Malaria (CNRFP), Burkina-Faso, participated in subse-
quent phases of development. Tablet strengths were
designed to fit predictions based on optimal dose ranges
and anthropometric (age/weight) parameters [7]. Early
investigations on the development of a fixed co-formula-
tion focused on the compatibility between artesunate
and amodiaquine, and feasibility and stability studies of
a fixed-dose co-formulation [2].
This paper recounts the development process that led
to the formulation of ASAQ in bilayer tablets up to the
clinical batches used for initial clinical studies performed
in Burkina Faso [8], and subsequently transferred to
commercial partners identified by DNDi (Sanofi-Aventis
in 2005, Bompart F, Kiechel JR, Sebbag R, Pecoul B:
Innovative public-private partnership to maximize the
delivery of anti-malarial medicines: lessons learned from
the ASAQ Winthrop experience, submitted).
Methods
Chemicals
Artesunate (AS) was purchased from Knoll, Switzerland
(currently Abbott Laboratories) and amodiaquine hydro-
chloride (AQH) salt (AQ.2HCl.2H2O) and amodiaquine
base (AQb) were obtained from Parke Davis, Senegal
and Ipca, India. Dihydroartemisinin (DHA), AS main
metabolite, was provided by Knoll. Solvents and buffers
were of analytical grade. Tablet excipients were of phar-
maceutical grade. The physicochemical properties of AS
and AQ were characterized and reported previously [2].
Analytical methods
Artesunate and DHA assay
AS was determined by HPLC with UV detection on
Varian ProStar model chromatograph apparatus
equipped with Hypersil C4 column, 5 μm, 250 mm ×
4.6 mm. Sodium acetate trihydrate 0.05 M/NaOH for
pH 5,2/acetonitrile mixture (63/37%V/V) was used as
the mobile phase with flow rate of 1.5 ml.min
-1.T h e
injection volume was 100 μl and the oven temperature
27°C, UV detector was set to 211 nm. In these condi-
tions, the retention time of AS was 8 minutes, that of
DHA of 11 and 16 minutes (the a and b DHA epimers,
respectively) and that of artemisinin of 10 minutes. The
analysis time was 15 minutes.
AS standard solution (1 mg mL
-1 in mobile phase) was
diluted in mobile phase to obtain calibration curve (n≥5)
for the desired concentration range. This method was
validated according to ICH guidelines. Further internal
specifications were implemented: RSD of 6 consecutive
injections < 2%.
Amodiaquine assay
AQ was dosed by spectrophotometry using PERKIN
ELMER lambda 20 Spectrophotometer at 342 nm with
cell thickness of 1 mm. AQ standard solution (89 mg of
amodiaquine hydrochloride completed to 50 mL with
1% HCl) was further diluted ten-fold with a 1% hydro-
chloric acid solution.
ASAQ tablet preparation and evaluation
Development strategy
From pre-formulation studies [2] it was clear that some
key parameters, namely water or humidity presence,
HCl release or AS AQ contact, have to be controlled for
suitable stability of obtained tablets. The development
was a series of pharmacotechnical manufacturing pro-
cesses beginning from the simplest one and going
Table 1 Target product profile of developed ASAQ formulation
Attribute Target product characteristics
API AS and AQ
Population targeted pediatric and adult
Posology based on [7]
ASAQ low strength 25/67.5 mg (equivalent AQ base) for children
ASAQ high strength 100/270 mg (equivalent AQ base) for older children and adults
Drug release rapid disintegration and fast drug release (> 75% in 45 minutes in vitro dissolution test, Pharmacopoeia standards)
Drug form compatible with pediatric use: minimal size for facilitating swallowing; a fixed dose combination
Stability/Conditioning compatible with climatic zone IV (tropical conditions): ICH Q1A(R2)
Cost < 1$
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blems raised regarding target product profile. The aim
was to obtain a stable ASAQ tablet with the simplest
possible technology. First, direct compression was dis-
carded, then granulation step was considered (aqueous,
alcoholic and dry), with or without excipients to
enhance tablet stability (pH regulator, hydrophobic
agent...). The optimized process ended up with the
choice of a bilayer ASAQ tablet.
Tablet preparation
In all monolayer ASAQ tablets, sodium croscarmellose
(Acdisol
®) was used as diluent/desintegrant, polyvinyl-
pyrrolidone (PVP K30
® or K25
® 12%/16% aqueous solu-
tion) as a binder, colloidal silica (Aerosil
® 300) as
flowing agent, and magnesium stearate was used as
lubricant. The different components were sieved
through a 1 mm grate, AQ was sieved through a 250
μm mesh diameter siever). All monolayer tablets were
compressed using a rotary SVIAC PR6 tablet press
equipped with 2 round 13 mm diameter punches.
Several preparation techniques were used to optimize
ASAQ tablets. In tablets prepared by wet granulation,
internal phase constituents (AS, AQ and a part of Acdi-
sol
® for batch n° 20399, AQ and Acdisol
® for batch n°
20454) were mixed in a planetary mixer and moistened
with 12% PVP K30
® solution and 16%PVPK25
® solution
respectively. The moist mass was then passed through
1.6 mm mesh of oscillating granulator and dried in fluid
air bed dryer at 60°C for 35 minutes. After drying, gran-
ulate was screened again (0.80 mm mesh), mixed with
external phase constituents (lubricants and 1%w/w of
Acdisol
® for batch 20399, AS and CaCO3 in addition in
batch n° 20454) before compression.
Dry granulation tablets (batches 30411-30439) were
prepared using POWTEC RC 100 × 30 compactor
equipped with a rotative calibrator for AQ alone com-
paction. The plates obtained were calibrated through a
0.8 mm screen and then mixed in planetary mixer with
other excipients.
Some batches (30412, 30437, 30439) contained addi-
tional colloidal silica (Aerosil
® 300) as hydrophobic
agent and some were manufactured under controlled
conditions (batches 30436-30439). The bilayer tablet
manufacturing process is summarized in Figure 2. All
tablet pharmacotechnical controls (mass uniformity, dis-
integration time, hardness) were performed according to
Pharmacopoeia standards unless specified otherwise.
Tablet stability and pre-stability studies
For short-term pre-stability studies, tablets were placed
in sealed glass vials at 25°C/60% RH and 40°C/75% RH
according to ICH guidelines ICH QA1(R2). In the
absence of tropical zone ambient storage department, 60
month stability study of bilayer tablets was carried out in
CHU Pellegrin hospital official drug storage department,
France at 15 to 25°C and ambient humidity. Tablets were
packaged in Alu/Alu blisters for optimized humidity pro-
tection. Several conditioned aliquots of each tablet batch
were analysed for AS, AQ and DHA content at defined
times. Regulatory stability studies for ASAQ formulations
were further performed by Sanofi-Aventis.
Tablet AS and DHA content determination
10 or 20 tablets were finely powdered in a mortar. An
aliquot of 1,4 g was put into a 100 ml volumetric flask,
completed after stirring with water/ethanol (40/60%V/V)
and filtered through a 0.45 μm filter. 50 μl were injected
according to the HPLC AS method described above. AS
was quantified by comparison with a test solution of 2
mg/ml in water/ethanol (40/60%V/V). The specifications
used were AS content (100 mg or 25 mg) ± 5%w/w
(according to ICH specifications) and further internal
specifications for DHA content < 3% after 36 months
aging (< 1% DHA in short term studies) were applied,
as DHA indicated an ongoing AS degradation process.
Tablet AQ content determination
10 or 20 tablets were finely powdered in a mortar. An
aliquot of 700 mg was put into a 200 ml volumetric
flask, dissolved in 150 ml 0.1N HCl sonicated for 10
minutes and electromagnetically stirred for 20 minutes
and completed. The obtained solution was filtered
through a 0.45 μm filter, diluted ten-fold in HCl 0.1N
and analysed using AQ spectrophotometric method
described. AQ was quantified comparing to test solution
of 88 mg AQH dissolved in 50 ml 0,1N HCl and diluted
Figure 2 Bilayer tablets manufacturing process.
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or 67 mg) ± 5% w/w (ICH stability study specifications).
ASAQ tablet dissolution test
Dissolution studies were carried out in 500 ml and 900
ml of 11.4 g.l
-1 sodium acetate and 0.886 g.l
-1 acetic acid
aqueous solution adjusted to pH 5.5 for low dosage (25
mg AS 67.5 mg AQ) and high dosage (100 mg AS 270
mg AQ) ASAQ tablets respectively, using European phar-
macopoeia apparatus 2 (100 rpm, 37°C). At defined times
(15, 30, 45, 60, 90 minutes) samples were withdrawn with
10 μm porous prefilter equipped syringes. Drug concen-
tration in sample was determined using previously
described HPLC method for AS and DHA and UV spec-
trophotometric method for AQ and comparing dissolu-
tion samples to standard solutions. The specifications
were AQ and AS drug release > 75% at 45 minutes.
Results
Direct compression
A direct compression process proved not feasible as AQ
compressibility was poor and the high-strength tablets
required too large a quantity of excipients for an accep-
table tablet size.
Aqueous wet granulation
The initial wet granulation monolayer tablet formulation
containing sodium croscarmellose, PVP K30, magnesium
stearate and silicone dioxide was found unstable leading
to 9% AS loss after 3 months at 40°C/75%RH [2]. When
this process was adapted to industrial scale (modifica-
tion of wet granulation parameters, flowability and com-
pressibility improvement), AS degradation increased and
only 83.7 and 79.6% of AS were found for the high and
low-strength ASAQ tablets respectively after 2 months
at 40°C/75%RH.
Several approaches were considered to avoid pre-
viously identified factors that affect AS degradation
(such as humidity, released HCl and AQ contact, [2]):
incorporation of AS in the tablet external phase, inclu-
sion of pH regulator, alcoholic wet granulation, dry
granulation, increased hydrophobic agents, tablet manu-
facturing in controlled conditions, physical separation
between AS and AQ (bilayer tablets).
AS in external phase
AS was incorporated in the external tablet phase (after the
granulation step) in order to avoid direct contact with
water during aqueous wet granulation of AQ. Tablets
were found stable during two months at 40°C/75%RH, but
17% AS degradation occurred during the third month.
pH regulator
CaCO3 and NaHCO3 were tested as pH regulators in
order to neutralize the effects of the possible release of
HCl which was shown to induce rapid AS degradation
[2]. As NaHCO3 precipitated during the dissolution
test, CaCO3 was selected. Increasing quantities of car-
bonate were studied for the buffer effect conferred to
ASAQ tablets while adding HCl in the dissolution
medium (Figure 3). 17%w/w was selected as optimal
CaCO3 tablet content for further investigation combin-
ing buffering power and technical ease. When this for-
mulation was submitted to accelerated stability
conditions (40°C/75%RH,) AS degradation was delayed
compared to tablets without CaCO3, but occurred
nevertheless after three months. The presence of
CaCO3, while further improving tablet stability in
other dry granulation formulations (see Figure 4, batch
n° 30436 with pH regulator vs. 30438 without), was
not sufficient to guarantee the absence of AS degrada-
tion in the tested conditions.
Alcoholic wet granulation
To avoid direct water contact, alcoholic granulation was
tried. Several formulations were tested and the perfor-
mances of some of them are summarized in Table 2.
Globally, besides avoiding direct contact with water,
alcoholic compared to aqueous granulation improved
tablets disintegration, which was one of main pharmaco-
technical specifications, but increased their friability. No
immediate incompatibility was noticed. However, scale
transposition of alcoholic granulated tablets was consid-
ered to have too many constraints at industrial scale.
Stability studies of these formulations were hence not
pursued.
Dry granulation process
Beyond avoiding water contact, which was the first
objective of dry granulation studies, this process was
particularly suitable for developed formulation, as a
Figure 3 Buffer effect of ASAQ tablets containing pH regulator
(CaCO3) while adding HCl 0,1N.
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Page 5 of 12small tablet size was required. AS was added in the
external phase of tablets and 17% pH regulator content
included. Dry granulation tablet stability was largely
improved (> 95% AS and 100% AQ after three months
at 40°C/75%RH; batch n° 30411, Figure 4) compared to
wet granulation tablets (84% AS; batch n° 20454 Figure
3) with the same formulation (containing pH regulator).
Nevertheless 3.4% of DHA found in dry granulation
tablets indicated ongoing AS degradation.
Hydrophobic agent
To further reduce negative water impact on AS stability
in ASAQ tablets, higher silicon dioxide percentage (1.9%
w/w, contrarily to 0.9%w/w used as flowing agent in
initial and all further formulations) was added to AS in
external phase to improve its hydrophobic properties.
However AS degradation increased in the presence of
higher content of silicon dioxide in all tested formula-
tions (e.g. batch n° 30412 vs. 30411) (Figure 4).
Controlled temperature and humidity conditions
To prevent ASAQ tablets from humidity contact, tablets
(batch n° 30435 to 30438) were manufactured in con-
trolled conditions (21°C ± 3°C and 32 ± 4%RH). These
conditions enhanced AS stability (Figure 4) as AS con-
tent was stable after a three-month stability study, and
as the DHA content decreased compared to non-con-
trolled conditions (2.2% vs. 3.4% DHA respectively).
However, this was considered not enough to warrant
further development. Since all the approaches above had
failed and since basic quinoline structures (like AQ) as
well as the presence of HCl appeared to be involved in
AS degradation [2], the physical separation between the
two APIs was the next option to be considered.
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A bilayer ASAQ tablet formulation was developed to
minimize the direct contact between AS and AQ. Table 3
summarizes the characteristi c so ft h i sf o r m u l a t i o nf o r
both low- and high-strength bilayer ASAQ tablets. The
pharmacotechnical properties of the tested formulations
are summarized in Table 4.
Bilayer tablets showed excellent results in pre-stability
studies (Table 5), as APIs content remained stable over
three months at 40°C/75%RH and no DHA was detect-
able, contrarily to monolayer tablets or even to commer-
cially available single-agent reference AS tablets,
Arsumax
® (Sanofi-Aventis).
Long-term and accelerated stability studies (60 months
ambient conditions, see Figure 5; 12 months at 30°C/
65%RH; and 6 months at 40°C/75%RH see Table 6)
were then started.
Dissolution tests were performed on ASAQ bilayer
tablets compared to the individually formulated standard
product: AS Arsumax
® tablets and AQ Flavoquine
®
tablets. Arsumax
® AS drug release profile was similar to
bilayer AS drug release profile (Figure 6, panel A)
whereas Flavoquine
® AQ profile was slightly delayed
compared to the bilayer tablets (Figure 6, panel B). All
profiles met Pharmacopoeia requirements for rapid drug
release (i.e. > 75% drug released in 45 min).
Table 2 Pharmacotechnical characteristics of ASAQ alcoholic/aqueous granulation tablet formulations with or without
binder*
Batch n° 11128G 11213(1) 11129 11128P 11124 11130
Tablet dosage AS/AQ (mg/mg) 100/270 100/270 100/270 25/67,5 25/67,5 25/67,5
Granulation Aqueous +
PVP*
Alcoholic +
PVP*
Alcoholic without
PVP*
Aqueous +
PVP*
Alcoholic +
PVP*
Alcoholic without
PVP*
Mean tablet weight (mg) 494 480 476 129 123 120
Hardness (N) 73 65 69 72 60 59
Disintegration time (min) 4 < 1 < 1 5 < 3 < 3
Friability (%) 1.25 ND 2.6 0.7 ND 1.04
Drugs released after 45 min of dissolution test
(AQ%/AS%)
92/76 94/83 98/91 100/86 ND 100/106
Key: ND = not determined; binder = PVP K30 10% solution.
Table 3 Bilayer ASAQ tablet formulation for high dosage and low dosage ASAQ tablets
Composition Content
(%w/w)
Quantity (mg/tablet)
Layer 1 (blend no 30154C01 ) high dosage tablet (batch 30154C03) low dosage tablet (batch 30154C04)
Dry granulated AQH 50.38 352.64 88.16
Sodium Croscarmellose (AcDiSol) 1.40 9.80 2.45
Polyvinylpyrrolidone (PVP K30) 1.14 8.00 2.00
Magnesium stearate 1.32 9.26 2.315
Silicon dioxide (Aerosil 300) 0.11 0.75 0.1875
Ca carbonate 7.71 54.00 13.50
Total layer 1 62.06 434.45 108.61
Layer 2 (blend 30154C03)
AS 14.29 100.00 25.00
Polyvinylpyrrolidone (PVP K30) 1.14 8.00 2.00
Sodium Croscarmellose (AcDiSol) 1.40 9.80 2.45
Magnesium stearate 0.43 3.00 0.75
Silicon dioxide (Aerosil 300) 0.11 0.75 0.1875
Calcium carbonate 7.71 54.00 13.50
Microcrystalline cellulose 12.86 90.00 22.50
Total layer 2 37.94 265.55 66.39
Total 100.00 700.00 175.00
Lacaze et al. Malaria Journal 2011, 10:142
http://www.malariajournal.com/content/10/1/142
Page 7 of 12Discussion
Pharmaceutical issues
AS is easily degraded by heat and aqueous conditions
[9,10]. The key factors for AS degradation have been
identified in pre-formulation studies as the combination
of humidity (> 1%w/w) and temperature (≥40°C) on one
hand (typically tropical conditions), and the presence of
AQ (or another quinoline, e.g. quinine) and/or HCl on
the other hand [2].
To prevent AS degradation several strategies were
tried and many proved inadequate:
◦ Formulating AQ in the inner phase and AS in the
external phase of tablets.
◦ Reducing residual water presence in the tablets
either through wet or dry granulation. For alcoholic wet
granulation, handling 95% ethanolic solution at indus-
trial scale was not possible. Replacing wet granulation
by dry granulation (AQ powder was not suitable for
direct compression) was not sufficient to ensure AS sta-
bility and the addition of an hydrophobic agent (silicon
dioxide) increased AS degradation, possibly through
radical interaction [11].
◦ Manufacturing in controlled atmospheric conditions
still led to > 5% AS tablet content loss after 3 months at
40°C/75%RH.
◦ Adding a pH regulator (CaCO3) improved partly AS
stability but did not prevent degradation completely in
dry granulation tablets even when combined with con-
trolled atmospheric conditions manufacturing as some
DHA was still detected.
◦ Controlled atmosphere conditions manufacturing did
not meet cost requirements. Tablet protective coating
was not considered as a suitable condition to avoid
water contact.
In all the formulations above, residual humidity (see
Table 4) in tablets exceeded the 1%w/w limit identified in
pre-formulation studies for AS degradation [2]. Instead,
experimental batches of bilayer ASAQ tablets, whereby
the two active ingredients are physically isolated, met sta-
bility and dissolution criteria. Despite an initial water
content slightly > 1%w/w (1.5% and 1.3% for AQ and AS
granulate respectively) tablet drug content was stable for
at least six months in accelerated stability conditions and
for 60 months at 25°C/60%RH when packaged in alu/alu
blisters (particularly adapted to storage in hot and humid
areas like the tropics). In vitro drug release from these
tablets was comparable to commercially available single-
agent reference products. The disposition in healthy
human subjects of the fixed-dose tablets was comparable,
though not completely bio-equivalent, to the individually
formulated drugs [12]. Furthermore, 60 months stability
study of our pilot batch of ASAQ in ambient European
conditions augurs well for the long-term stability of the
formulation. If these results are confirmed in zone IV
conditions, the product shelf life (currently 36 months)
could be further extended, which would simplify drug
procurement, storage and delivery.
Project network
Establishing and running the operations of the FACT
network proved challenging but rewarding. The project
Table 4 Pharmacotechnical properties of various ASAQ monolayer and bilayer tablet formulations
30154C01
Batch n° 20454 30411 30412 30436 30437 30438 30439 layer AQ layer AS
Formulation tablet monolayer bilayer
granulation wet aq. dry
Blend control Flowability (s/100 g) 5 6 9 11 11 7 11 NA NA
Hausner index (Vo/Vf) 1.25 1.19 1.21 1.23 1.10 1.20 2.24 1.09 1.41
Tablet control Mass (mg) 589.2 622.6 636.7 623.4 622.6 613.8 624 434.5 265.5
700
Hardness (N) 61 80 63 78 68 74 71 46
Friability (%) 1.50 1.27 1.39 1.80 2.55 2.23 1.79 0.31
Residual humidity (%) 6 ND* ND** 1.84 1.44 1.19 1.07 1.49 1.31
Disintegration (min) 3.0 1.8 1.6 1.5 1.4 6.1 4.1 < 1.5
Key: NA: data not available.
*Residual humidity not determined, Karl Fischer water content 6.35%.
** Residual humidity not determined, Karl Fischer water content 6.33%.
Table 5 AS and DHA recovery after 3 months in
accelerated aging conditions (40°C/75%RH)
AS content (%) DHA content (%)
Arsumax
® > 95 3.3
Monolayer ASAQ tablet 97.8 3.4
Bilayer ASAQ tablet 99.1 < LOQ
Comparison between monolayer tablets with pH regulator (batch n° 30411),
bilayer high dosage tablets (batch n° 40166) and commercially available
reference of AS tablets, Arsumax
®.
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initial seed funds from WHO/TDR to the Biopharmacy
Laboratory of Bordeaux2 University for validation of the
pre-formulation [2], funding was provided by DNDi,t h e
European Commission INCO-DEV programme, MSFand
TDR [13]. Most participating institutions donated per-
sonnel costs. When the project was passed onto Sanofi-
Aventis for registration and commercialization in 2004,
the company complemented with the chemistry, manu-
facturing and control part of the dossier for the product
manufactured at industrial scale, which also included
pharmaceutical and clinical studies. Overall, the project
required five years from the bench to registration. Both
the timelines and the costs are comparatively lower by
orders of magnitude to the typical R&D process of a
new chemical entity conducted by the pharmaceutical
industry. In this case, the cost of failure in the early
phases of pharmaceutical development was absorbed by
the initial funders. Both, DNDi, Sanofi-Aventis and TDR
have continued to invest in phase 4 and implementation
studies.
To conduct this project, the team in Bordeaux set up
a public-private regional partnership, TropiVal, involving
laboratories from Bordeaux 2 University for research on
pre-formulations, Bordeaux Hospital for stability studies,
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Figure 5 Long-term stability study of ASAQ bilayer Aluminium blistered tablets in ambient conditions. AS & AQ content (Y axis) and
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Table 6 Drug recovery (%) in ASAQ bilayer tablets after 6
months in various aging conditions
25°C/60%
RH
30°C/65%
RH
40°C/75%
RH
High dosage
tablets
AS (%) 100.2 100.7 96.1
AQ
(%)
100.3 102.0 99.6
Low dosage
tablets
AS (%) 102.0 102.0 99.2
AQ
(%)
101.7 102.7 101.8
Batches 30154C03 and 30154C04 for high and low dosage respectively, DHA
< 0,5%.
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Page 9 of 12the start-up COMIPSO for identification of degradation
products, CREAPHARM (today UNITHER) for blister-
ing, ELLIPSE Pharmaceuticals for process identification,
development and validation of the bilayer ASAQ tablet,
and ROTTENDORF Pharma for the manufacturing of
the clinical batch (Figure 7). Each public partner
accepted to work on the project either at cost or no fee
(the Bordeaux University Hospital offering for many
years free storage of ASAQ in regulatory conditions for
stability studies), without counting human resources.
Technology transfer from the University Sains Malaysia
provided South-North links. However, the Bordeaux
Tropival network was later terminated as it was found
not sustainable; the university and the private partners
could not secure the seed funds required to initiate
projects ahead of larger partnerships with appropriate
funding being established. Tropival’sc o n c e p ti sn o w
integrated within the Pharmaceutical and analytical
development applied to neglected diseases and counter-
feit drugs research unit of the University Bordeaux
Segalen.
The product was developed as public good and
together with DNDi, ELLIPSE Pharmaceuticals decided
to forsake the intellectual property rights associated to
the process. The rights of producing and commercializ-
ing the product were initially transferred in 2005 by
DNDi to Sanofi-Aventis with a time-limited exclusivity
agreement until registration. ASAQ (Coarsucam
® and
Artesunate-Amodiaquine Whintrop
®,S a n o f i - A v e n t i s )
was first registered in 2007, three years after technology
transfer, and WHO pre-qualified in 2009. The absence
of intellectual property removed barriers to access and
wider production as the exclusivity was time limited and
is now expired. On the other hand, this approach may
be difficult to replicate in all situations; while it relies
heavily on partners absorbing part of the costs and
risks, or working at cost, there is clearly no or limited
prospects for return for those (typically in this case, the
public sector) that allocate resources and take the risks
inherent in the early phases of pharmaceutical develop-
ment. Together, this paper and Kauss et al [2] provide a
comprehensive account of the process that, through
trials and errors, identified a suitable pharmaceutical
form for industrial scale-up and was further developed
for commercialization (Bompart F, Kiechel JR, Sebbag R,
Pecoul B: Innovative public-private partnership to maxi-
mize the delivery of anti-malarial medicines: lessons
l e a r n e df r o mt h eA S A QW i n t h r o pe x p e r i e n c e ,s u b -
mitted). ASAQ is now registered and available in several
malaria endemic countries.
Conclusions
The development of a stable co-formulation containing
AS and AQ in a bilayer tablet was a result of about three
years of pharmaceutical development under the public-
private partnership initiated by WHO and DNDi with
the not-for-profit and public sector in the lead. The
development process was hampered by financial issues
related to a lack of investment from the public sector.
This lead initially to development goals focusing more on
lowering the cost of manufacturing rather than on a
more expensive optimization process based on the isola-
tion of AS from AQ. This explains the delay in choosing
an orientation towards a bilayer tablet. DNDi has since
established a strong fund-raising capacity building to
allow completion of the FACT and other programmes.
TropiVal is now part of a scientific team aiming to
develop new pharmaceutical projects on drug develop-
ment for neglected diseases. Moreover, this experience
120
A
60
80
100
d
 
A
S
 
(
%
)
20
40
60
R
e
l
e
a
s
e
Batch 30154C03
Batch 30154C04
0
0 2 04 06 08 0 1 0 0
Time (min)
Arsumax®
100
120
B
40
60
80
l
e
a
s
e
d
 
A
S
 
(
%
)
0
20
40
R
e
l
Batch 30154C03
Batch 30154C04
Flavoquine®
0 2 04 06 08 0 1 0 0
Time (min)
Figure 6 Dissolution profiles of AS and AQ bilayer ASAQ
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Page 10 of 12demonstrates that a network of scientists associated with
industrial partners is able to lead to the production of
improved tools for disease control. Although fundamen-
tal research is the initial aim of a public research institu-
tion, providing experience in applied research and
technology transfer is likely to improve the relationship
between academia and industry.
The resulting branded product (Artesunate-Amodia-
quine Whintrop
®) is currently made available at manu-
facturing cost to the national malaria control
programmes of African and Asian endemic countries.
As no intellectual property right was claimed by the net-
work of scientists and industrials involved in the initial
phase of the project, an exclusivity contract allowing
technology transfer was signed between DNDi and
Sanofi-Aventis. The contract expired at the time of
registration of ASAQ and the rights of producing and
commercializing the product are now open and can be
transferred to any other interested commercial partner.
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